abstral

halaven

Sublingual tablet with fast onset of action for the treatment of breakthrough pain in cancer patients.

Name Abstral®
Description Abstral™ provides fast and effective treatment of breakthrough pain in cancer patients. Abstral™ combines quick-dissolving sublingual tablet technology and the analgesic, fentanyl.
Active Substance Fentanyl
Indication Breakthrough cancer pain.
Strengths 100, 200, 400 μg
Regulatory Status

EMA approved June 2008; FDA approved January 2011.
Inserts Code #783939. Revision Date: March 2010.
Currently registered in Bahrain, Kuwait, Qatar, Oman, UAE, and Lebanon.
Under registration in KSA, Iraq, Egypt, Algeria, Morocco and Tunisia
Business Partner Kyowa Hakko Kirin Co. Ltd
halaven